Recombinant human IL-15 Trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3634-3640

  Laprevotte, Emilie ^a,b,c,d   Voisin, Gregory ^a,b,c,d   Ysebaert, Loïc ^a,b,c,d   Klein, Christian ^e   Daugrois, Camille ^a,b,c,d   Laurent, Guy ^a,b,c,d   Fournie, Jean Jacques ^a,b,c,d   Quillet Mary, Anne ^a,b,c,d  

^a CHU PURPAN   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Institut Carnot Lymphome: CALYM   (France)

^d Laboratoire d'Excellence Toulouse Cancer TOUCAN   (France)

^e Roche Glycart AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD20 ANTIBODY; OBINUTUZUMAB; RECOMBINANT INTERLEUKIN 15; RITUXIMAB;

ACCESSORY CELL; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CELL INTERACTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RECEPTORS, IGG; RECOMBINANT PROTEINS;

EID: 84885104733     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300187     Document Type: Article

References (49)

1. Wang, X., P. Lupardus, S. L. Laporte, and K. C. Garcia. 2009. Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 27:29-60.
2. Meazza, R., B. Azzarone, A. M. Orengo, and S. Ferrini. 2011. Role of commongamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J. Biomed. Biotechnol. 2011:861920.
3. Becknell, B., and M. A. Caligiuri. 2005. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv. Immunol. 86:209-239.
4. Stonier, S. W., and K. S. Schluns. 2010. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol. Lett. 127:85-92.
5. Huntington, N. D., N. L. Alves, N. Legrand, A. Lim, H. Strick-Marchand, J. J. Mention, A. Plet, K. Weijer, Y. Jacques, P. D. Becker, et al. 2011. IL-15 transpresentation promotes both human T-cell reconstitution and T-celldependent antibody responses in vivo. Proc. Natl. Acad. Sci. USA 108:6217-6222.
6. Lee, G. A., Y. H. Liou, S. W. Wang, K. L. Ko, S. T. Jiang, and N. S. Liao. 2011. Different NK cell developmental events require different levels of IL-15 transpresentation. J. Immunol. 187:1212-1221.
7. Fehniger, T. A., and M. A. Caligiuri. 2001. Interleukin 15:biology and relevance to human disease. Blood 97:14-32.
8. Jakobisiak, M., J. Golab, and W. Lasek. 2011. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 22:99-108.
9. Bhat, R., and C. Watzl. 2007. Serial killing of tumor cells by human natural killer cells-enhancement by therapeutic antibodies. PLoS ONE 2:e326-e332.
10. Steel, J. C., T. A. Waldmann, and J. C. Morris. 2012. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33:35-41.
11. de Totero, D., R. Meazza, M. Capaia, M. Fabbi, B. Azzarone, E. Balleari, M. Gobbi, G. Cutrona, M. Ferrarini, and S. Ferrini. 2008. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood 111:517-524.
12. Söderberg, O. 1998. Growth and survival of B-chronic lymphocytic leukaemia cells. Med. Oncol. 15:73-78.
13. Burger, J. A., N. Tsukada, M. Burger, N. J. Zvaifler, M. Dell'Aquila, and T. J. Kipps. 2000. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96:2655-2663.
14. Aguilar-Santelises, M., D. Gigliotti, L. M. Osorio, A. D. Santiago, H. Mellstedt, and M. Jondal. 1999. Cytokine expression in B-CLL in relation to disease progression and in vitro activation. Med. Oncol. 16:289-295.
15. Schröttner, P., M. Leick, and M. Burger. 2010. The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact. Ann. Hematol. 89:437-446.
16. Hallek, M., K. Fischer, G. Fingerle-Rowson, A. M. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. von Grünhagen, et al; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. 2010. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164-1174.
17. Glennie, M. J., R. R. French, M. S. Cragg, and R. P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44:3823-3837.
18. Harjunpää, A., S. Junnikkala, and S. Meri. 2000. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51:634-641.
19. Bologna, L., E. Gotti, M. Manganini, A. Rambaldi, T. Intermesoli, M. Introna, and J. Golay. 2011. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J. Immunol. 186:3762-3769.
20. Golay, J., M. Manganini, V. Facchinetti, R. Gramigna, R. Broady, G. Borleri, A. Rambaldi, and M. Introna. 2003. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 88:1002-1012.
21. Ysebaert, L., E. Gross, E. Kühlein, A. Blanc, J. Corre, J. J. Fournié, G. Laurent, and A. Quillet-Mary. 2010. Immune recovery after fludarabine-cyclophosphamiderituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 24:1310-1316.
22. Mössner, E., P. Brünker, S. Moser, U. Püntener, C. Schmidt, S. Herter, R. Grau, C. Gerdes, A. Nopora, E. van Puijenbroek, et al. 2010. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393-4402.
23. Czuczman, M. S., and S. A. Gregory. 2010. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk. Lymphoma 51:983-994.
24. Hallek, M., and N. Pflug. 2011. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev. 25:1-9.
25. Le Garff-Tavernier, M., J. Decocq, C. de Romeuf, C. Parizot, C. A. Dutertre, E. Chapiro, F. Davi, P. Debré, J. F. Prost, J. L. Teillaud, et al. 2011. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 25:101-109.
26. Moga, E., E. Alvarez, E. Cantó, S. Vidal, J. L. Rodríguez-Sánchez, J. Sierra, and J. Briones. 2008. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp. Hematol. 36:69-77.
27. Moga, E., E. Cantó, S. Vidal, C. Juarez, J. Sierra, and J. Briones. 2011. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor betamediated immunosuppression. Exp. Hematol. 39:1064-1071.
28. Suck, G., V. Y. Oei, Y. C. Linn, S. H. Ho, S. Chu, A. Choong, M. Niam, and M. B. Koh. 2011. Interleukin-15 supports generation of highly potent clinicalgrade natural killer cells in long-term cultures for targeting hematological malignancies. Exp. Hematol. 39:904-914.
29. Laprevotte, E., L. Ysebaert, C. Klein, W. Valleron, A. Blanc, E. Gross, G. Laurent, J. J. Fournié, and A. Quillet-Mary. 2013. Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. Leuk. Res. 37:440-446.
30. Seiffert, M., A. Schulz, S. Ohl, H. Döhner, S. Stilgenbauer, and P. Lichter. 2010. Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood 116:4223-4230.
31. Lim, S. H., A. T. Vaughan, M. Ashton-Key, E. L. Williams, S. V. Dixon, H. T. Chan, S. A. Beers, R. R. French, K. L. Cox, A. J. Davies, et al. 2011. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118:2530-2540.
32. Bowles, J. A., and G. J. Weiner. 2005. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J. Immunol. Methods 304:88-99.
33. Bowles, J. A., S. Y. Wang, B. K. Link, B. Allan, G. Beuerlein, M. A. Campbell, D. Marquis, B. Ondek, J. E. Wooldridge, B. J. Smith, et al. 2006. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108:2648-2654.
34. Jahrsdörfer, B., S. E. Blackwell, J. E. Wooldridge, J. Huang, M. W. Andreski, L. S. Jacobus, C. M. Taylor, and G. J. Weiner. 2006. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 108:2712-2719.
35. Epron, G., P. Ame-Thomas, J. Le Priol, C. Pangault, J. Dulong, T. Lamy, T. Fest, and K. Tarte. 2012. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia 26:139-148.
36. Rosenberg, S. A., M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, J. M. Skibber, E. Shiloni, J. T. Vetto, et al. 1985. Observations on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313:1485-1492.
37. Lotze, M. T., Y. L. Matory, A. A. Rayner, S. E. Ettinghausen, J. T. Vetto, C. A. Seipp, and S. A. Rosenberg. 1986. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764-2772.
38. Gertner-Dardenne, J., C. Bonnafous, C. Bezombes, A. H. Capietto, V. Scaglione, S. Ingoure, D. Cendron, E. Gross, J. F. Lepage, A. Quillet-Mary, et al. 2009. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 113:4875-4884.
39. Cheever, M. A. 2008. Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222:357-368.
40. Berger, C., M. Berger, R. C. Hackman, M. Gough, C. Elliott, M. C. Jensen, and S. R. Riddell. 2009. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114:2417-2426.
41. Waldmann, T. A., E. Lugli, M. Roederer, L. P. Perera, J. V. Smedley, R. P. Macallister, C. K. Goldman, B. R. Bryant, J. M. Decker, T. A. Fleisher, et al. 2011. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117:4787-4795.
42. Scrivener, S., R. V. Goddard, E. R. Kaminski, and A. G. Prentice. 2003. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk. Lymphoma 44:383-389.
43. Ramsay, A. G., A. J. Johnson, A. M. Lee, G. Gorgün, R. Le Dieu, W. Blum, J. C. Byrd, and J. G. Gribben. 2008. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118:2427-2437.
44. Dall'ozzo, S., C. Kantari, G. Cartron, C. Le Guellec, P. Bardos, H. Watier, and G. Thibault. 2005. Major role of the effector to target ratio in rituximab mediated B cell depletion and interferon-γ production by NK cells: relevance in NHL and B-cell CLL. J. Clin. Oncol. 23(June 1 Suppl.):2566.
45. Wu, Z., and Y. Xu. 2010. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 antitumor action through NK and CD8+ T cells proliferation and activation. J. Mol. Cell Biol. 2:217-222.
46. Lotz, M., E. Ranheim, and T. J. Kipps. 1994. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J. Exp. Med. 179:999-1004.
47. Kremer, J. P., G. Reisbach, C. Nerl, and P. Dörmer. 1992. B-cell chronic lymphocytic leukaemia cells express and release transforming growth factor-beta. Br. J. Haematol. 80:480-487.
48. Trotta, R., J. Dal Col, J. Yu, D. Ciarlariello, B. Thomas, X. Zhang, J. Allard, II, M. Wei, H. Mao, J. C. Byrd, et al. 2008. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol. 181:3784-3792.
49. Evans, R., J. A. Fuller, G. Christianson, D. M. Krupke, and A. B. Troutt. 1997. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumorbearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell. Immunol. 179:66-73.